NEW YORK, NY, March 1, 2023 — Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions” or the “Company”) (Nasdaq: INBS), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced that on February 27, 2023, the Company received a notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)…
NEW YORK, February 16, 2023 — Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions” or the “Company”) (Nasdaq: INBS), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced that the Company has filed a 513(g) submission with the United States Food and Drug Administration (FDA) for its Intelligent Fingerprinting Drug Screening…
NEW YORK, February 14, 2023 — Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions” or the “Company”) (Nasdaq: INBS), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced its financial results for its fiscal second quarter ended December 31, 2022, and provided a business update. All amounts are expressed in U.S. dollars…
NEW YORK, February 7, 2023 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), today announced that Boughey Distribution (“Boughey”), one of the United Kingdom’s leading logistics providers to the food industry, has selected the on-the-spot fingerprint test from the Company’s subsidiary, Intelligent Fingerprinting, to support its random drug screening program, replacing its previous urine-based test….
NEW YORK, January 31, 2023 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), today announced that global garden equipment manufacturer Hozelock will implement drug tests utilizing fingerprint sweat-based technology from the Company’s subsidiary, Intelligent Fingerprinting, to promote employee safety. Hozelock will use the fingerprint sweat-based drug test to determine any recent employee use of…
NEW YORK, January 23, 2023 (GLOBE NEWSWIRE) – Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions” or the “Company”) (Nasdaq: INBS), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced it has successfully completed the review of results from Milestone 7, a phase of its biosensor platform development at the University of…
NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced that it has closed a Regulation S private placement (the “Transaction”) for expected aggregate gross proceeds of $220,585. The…
NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) – Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions” or the “Company”) (Nasdaq: INBS), today announced that its Board of Directors has cancelled the Company’s annual meeting of stockholders (for fiscal year ended June 30, 2021) that was originally scheduled to be held on June 16, 2022(the “FY21 Annual Meeting”), but…
NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) – Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions” or the “Company”) (Nasdaq: INBS), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced its preliminary financial results for the first financial quarter ended September 30, 2022 and provided a business update. Management will host a webcast and…
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced Eastern Airways is set to use an innovative drugs test that uses fingerprint sweat to help ensure…
New York, NY, October 31, 2022 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company delivering intelligent, non-invasive, real-time testing solutions, today announced that Goldstar Transport, the UK’s market-leading container haulier, has switched out urine tests for fingerprint drug testing. Goldstar employs approximately 600 LGV drivers, 170 office staff and 40…
New York, NY, October 26, 2022 – GBS Inc. (Nasdaq: GBS), now Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced that the Company has formally changed its name from GBS Inc. to Intelligent…
New York, NY, October 4, 2022 (GLOBE NEWSWIRE) — GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced it has acquired Intelligent Fingerprinting Limited (IFP), thus expanding the GBS platform of rapid, non-invasive diagnostic testing technologies. In addition, GBS…
The trial is single center, prospective study collecting coincident samples of oral fluids and blood to evaluate the time-course of glucose. New York, NY, July 13, 2022 (GLOBE NEWSWIRE) — GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced completion…
New York, NY, June 23, 2022 (GLOBE NEWSWIRE) – GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that the Company and the University of Newcastle in Australia have selected a site for its proprietary biosensor technology. “Maintaining momentum with…
